Tivic Health Granted U.S., European Patents

Tivic Health Systems Inc. has received patent grants from the United States Patent and Trademark Office (USPTO) and the European Patent Office (EPO).
 
U.S. Patent 12,011,592 and European Patent EP3615133, both titled, “Adaptive Trigger For a Microcurrent Stimulation Device,” protect device and methods used to identify preferred treatment points and trigger a treatment mode. Triggers can be programmed in various ways to improve device performance and ease of use.

European Patent EP3615134, titled, “Sinus Treatment Device With Adaptive Circuit,” protects the device and methods used to dynamically adjust the stimulation voltage applied during a treatment phase, allowing for personalized treatment. The dynamic changes in stimulation help to maximize comfort, enhance device performance, and enrich user experience.
 
“The adaptive design and personalization of treatment parameters are unique features of our intellectual property that make our existing product line effective, comfortable and easy to use,” Tivic Health Chief Scientific Officer Blake Gurfein said. “We are committed to continuing to build a robust intellectual property portfolio supporting both current and future products, including our emerging assets in non-invasive vagus nerve stimulation.”
 
Tivic Health is a commercial health tech company advancing bioelectronic medicine. Tivic Health’s technology platforms leverage stimulation of the trigeminal, sympathetic, and vagus nerve structures. Tivic Health’s non-invasive and targeted approach to the treating inflammatory chronic health conditions gives consumers and providers drug-free therapeutic solutions with high safety profiles, low risk, and broad applications. Tivic Health’s first commercial product, ClearUP, is a U.S. Food and Drug Administration-approved, award-winning, handheld bioelectronic sinus device. ClearUP is clinically proven, doctor-recommended, and is available through online retailers and commercial distributors.